Sexually Transmitted HCV Superinfection in 2 Patients With HIV/HCV-Coinfection
 |
|
2 cases of HCV superinfection resulting from sexual transmission identified by phylogenetic analysis in HIV/HCV-coinfected men who have sex with men
Format: Microsoft PowerPoint (.ppt) | File size: 329 KB | Date posted: 6/18/2008
Slide topics include:
|
Browse Slides by Date - Descending
The Role of Integrase Inhibitors in HIV Management
 |
|
Martin Markowitz, MD, presents findings on the function of integrase and the role of integrase inhibitors in the management of HIV disease.
Format: Microsoft PowerPoint (.ppt) | File size: 1,471 KB | Date posted: 6/13/2008
Slide topics include:
|
Low-Level Viremia Frequent and Transient, Usually Not Requiring Change in Therapy Due to Low Incidence of Clinical and Immunologic Complications
 |
|
In an observational study, approximately 30% of patients who had achieved undetectable HIV-1 RNA subsequently experienced transient viremia, but low-level viremia was not associated with clinical events, development of high-level viremia, or changes in CD4+ cell counts
Format: Microsoft PowerPoint (.ppt) | File size: 214 KB | Date posted: 6/12/2008
Slide topics include:
|
MONARK Study: Lopinavir/Ritonavir Monotherapy Less Effective Than Standard Triple Therapy Regimen in Antiretroviral-Naive HIV Patients
 |
|
In a randomized, open-label trial, lopinavir/ritonavir monotherapy did not achieve similar virologic response rates overall to standard triple-therapy containing NRTIs, but a subset of patients achieving early virologic response may benefit from simplified therapy
Format: Microsoft PowerPoint (.ppt) | File size: 278 KB | Date posted: 6/12/2008
Slide topics include:
|
Didanosine-Based Antiretroviral Therapy and Failure to Achieve SVR Associated With Fibrosis Progression in HIV/HCV-Coinfected Patients
 |
|
In a retrospective analysis, receipt of didanosine-based therapy and failure to achieve SVR to HCV therapy were the only baseline factors significantly associated with rapid progression of liver disease in multivariate analysis
Format: Microsoft PowerPoint (.ppt) | File size: 204 KB | Date posted: 6/11/2008
Slide topics include:
|
Improved Renal Function With Antiretroviral-Mediated HIV-1 Suppression in Patients With Low CD4+ Cell Count and Advanced Chronic Kidney Disease
 |
|
In a prospective, multicenter study, HIV-1 RNA suppression improved renal function in patients with ≥ stage II chronic kidney disease and baseline CD4+ cell counts < 200 cells/mm3
Format: Microsoft PowerPoint (.ppt) | File size: 207 KB | Date posted: 6/10/2008
Slide topics include:
|
Increasing Incidence of Non-AIDS–Defining Cancers in Cohort of HIV-Infected Patients
 |
|
In a retrospective analysis of malignancies in an urban HIV cohort, the incidence of non-AIDS–defining cancers increased since the introduction of HAART while the incidence of AIDS-defining cancers decreased
Format: Microsoft PowerPoint (.ppt) | File size: 218 KB | Date posted: 6/6/2008
Slide topics include:
|
Prospective HLA-B*5701 Testing Prevents Abacavir-Related Hypersensitivity Reactions
 |
|
In a prospective, randomized, double-blind trial, screening for the HLA-B*5701 allele prior to abacavir use eliminated immunologically confirmed hypersensitivity reactions
Format: Microsoft PowerPoint (.ppt) | File size: 215 KB | Date posted: 6/6/2008
Slide topics include:
|
PISCIS Cohort Illuminates Risk of Progression to AIDS or Death Associated With HCV Coinfection, Potential Benefit of Starting Treatment With CD4+ Count > 350 cells/mm3
 |
|
In addition to documenting an increased risk of disease progression or death in HCV-coinfected patients, PISCIS cohort data demonstrated significantly reduced risk of progression to AIDS in patients who initiated HAART with CD4+ cell counts 350-500 cells/mm3 compared with 200-350 cells/mm3.
Format: Microsoft PowerPoint (.ppt) | File size: 274 KB | Date posted: 6/4/2008
Slide topics include:
|
Expert Viewpoint: How Many Agents Does a Treatment-Experienced Patient Need?
 |
|
Use this PowerPoint Resource to accompany the presentation by W. David Hardy, MD, on determining the number of active agents for the treatment-experienced patient.
Format: Microsoft PowerPoint (.ppt) | File size: 508 KB | Date posted: 5/23/2008
Slide topics include:
|
New This Month: New Data on Abacavir and Implications for Treatment
 |
|
This resource slideset accompanies the presentation by our Program Directors, Kathleen E. Squires, MD; Kimberly Y. Smith, MD, MPH; and Andrew R. Zolopa, MD
Format: Microsoft PowerPoint (.ppt) | File size: 341 KB | Date posted: 5/23/2008
Slide topics include:
|
|
Use the following filters to quickly browse and download slides for your talks
Browse slides by:
All Slides by Date (271)
Program Type
Topic
Featured Content
Paul E. Sax, MD, discusses the latest data regarding when to start antiretroviral therapy.
Interact with Eric S. Daar, MD, in a new Virtual Presentation of clinical case scenarios.
Martin Markowitz, MD, discusses recent data involving the use of integrase inhibitors.
|
|